The most significant risk factor is concurrent use of insulin or insulin secretagogues (sulfonylureas like glipizide or glyburide, and meglitinides like repaglinide)
Hum Mol Genet 21(17):37763784
WECSL treatment did not extend the total travel distance but prolonged the time in the center zone in the OFT compared to the Lop group (Figures 2C,D)
Fixed drug eruptions are more commonly seen in people with dark skin and often present as a slate brown color due to pigmentary incontinence of melanophages in the upper dermis
Generic name Dosage form Drug class Indications Strengths Dose per injection semaglutide injection, solution GLP-1 Agonists weight loss 1 mg/1.5 ml0.68 mg/ml 0.25mg injection, solutionGLP-1 Agonistsweight loss2 mg/1.5 ml(1.34 mg/ml)0.5mg injection, solutionGLP-1 Agonistsweight loss4 mg/3 ml(1.34 mg/ml)1mg injection, solutionGLP-1 Agonistsweight loss6.8 mg/3 ml(2.27 mg/ml)1.7mg injection, solutionGLP-1 Agonistsweight loss9.6 mg/3 mL(3.2 mg/ml)2.4mg injection, solutionGLP-1 AgonistsType 2 DM2 mg/1.5 ml(1.34 mg/ml)0.25mg/0.5mg injection, solutionGLP-1 AgonistsType 2 DM4 mg/3 ml(1.34 mg/ml)0.5mg/1.0mg
Tirzepatide at the 15mg dose shows constipation rates around 16-17%, lower than both Retatrutide and Semaglutide
